1. Home
  2. NGNE vs SCHL Comparison

NGNE vs SCHL Comparison

Compare NGNE & SCHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$35.99

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Logo Scholastic Corporation

SCHL

Scholastic Corporation

HOLD

Current Price

$41.49

Market Cap

790.4M

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
SCHL
Founded
2003
1920
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Books
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
790.4M
IPO Year
2014
1995

Fundamental Metrics

Financial Performance
Metric
NGNE
SCHL
Price
$35.99
$41.49
Analyst Decision
Strong Buy
Hold
Analyst Count
7
1
Target Price
$63.57
$40.00
AVG Volume (30 Days)
174.1K
374.7K
Earning Date
05-08-2026
03-19-2026
Dividend Yield
N/A
1.99%
EPS Growth
0.93
3442.86
EPS
N/A
2.34
Revenue
N/A
$1,487,100,000.00
Revenue This Year
N/A
$1.88
Revenue Next Year
N/A
$4.05
P/E Ratio
N/A
$17.77
Revenue Growth
N/A
N/A
52 Week Low
$15.93
$22.69
52 Week High
$43.66
$48.07

Technical Indicators

Market Signals
Indicator
NGNE
SCHL
Relative Strength Index (RSI) 53.66 44.65
Support Level $31.83 $40.29
Resistance Level $43.66 $43.84
Average True Range (ATR) 2.07 1.77
MACD 0.05 -0.08
Stochastic Oscillator 72.75 44.58

Price Performance

Historical Comparison
NGNE
SCHL

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About SCHL Scholastic Corporation

Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.

Share on Social Networks: